HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism by �떊�쟾�닔 & �쑄二쇳샇
of January 17, 2014.
This information is current as
Calcium-Dependent Mechanism
Protein Kinase C and Is Secreted by a 
HMGB1 Is Phosphorylated by Classical
Kook Jin Lim, Ji Eun Choi and Jeon-Soo Shin
Young Joo Oh, Ju Ho Youn, Yeounjung Ji, Sang Eun Lee,
http://www.jimmunol.org/content/182/9/5800
doi: 10.4049/jimmunol.0801873
2009; 182:5800-5809; ;J Immunol 
References
http://www.jimmunol.org/content/182/9/5800.full#ref-list-1
, 36 of which you can access for free at: cites 56 articlesThis article 
Subscriptions
http://jimmunol.org/subscriptions
 is online at: The Journal of ImmunologyInformation about subscribing to 
Permissions
http://www.aai.org/ji/copyright.html
Submit copyright permission requests at: 
Email Alerts
http://jimmunol.org/cgi/alerts/etoc
Receive free email-alerts when new articles cite this article. Sign up at: 
Print ISSN: 0022-1767 Online ISSN: 1550-6606. 
Immunologists, Inc. All rights reserved.
Copyright © 2009 by The American Association of
9650 Rockville Pike, Bethesda, MD 20814-3994.
The American Association of Immunologists, Inc.,
 is published twice each month byThe Journal of Immunology
 at Y
onsei M
edical Library on January 17, 2014
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
 at Y
onsei M
edical Library on January 17, 2014
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
HMGB1 Is Phosphorylated by Classical Protein Kinase C and
Is Secreted by a Calcium-Dependent Mechanism1
Young Joo Oh,2* Ju Ho Youn,2* Yeounjung Ji,* Sang Eun Lee,* Kook Jin Lim,§ Ji Eun Choi,¶
and Jeon-Soo Shin3*†‡
High-mobility group box 1 protein (HMGB1) has been studied as a key mediator of inflammatory diseases, including sepsis.
Regulating secretion is important in the control of HMGB1-mediated inflammation. Previously, it was shown that HMGB1 needs
to be phosphorylated for secretion. In this study, we show that HMGB1 is phosphorylated by the classical protein kinase C (cPKC)
and is secreted by a calcium-dependent mechanism. For this study, RAW264.7 cells and human peripheral blood monocytes were
treated with PI3K inhibitors wortmannin, LY294002, and ZSTK474, resulting in inhibition of LPS-stimulated HMGB1 secretion,
whereas inhibitors of NF-B and MAPKs p38 and ERK showed no inhibition. Akt inhibitor IV and mammalian target of
rapamycin inhibitor rapamycin did not inhibit HMGB1 secretion. However, the PKC inhibitors Go¨6983 (broad-spectrum PKC),
Go¨6976 (cPKC), and Ro-31-7549 (cPKC) and phosphoinositide-dependent kinase 1 inhibitor, which results in protein kinase C
(PKC) inhibition, inhibited LPS-stimulated HMGB1 secretion. PKC activators, PMA and bryostatin-1, enhanced HMGB1 secre-
tion. In an in vitro kinase assay, HMGB1 was phosphorylated by recombinant cPKC and by purified nuclear cPKC from
LPS-stimulated RAW264.7 cells, but not by casein kinase II or cdc2. HMGB1 secretion was also induced by the calcium ionophore
A23187 and inhibited by the Ca2 chelators BAPTA-AM and EGTA. These findings support a role for Ca2-dependent PKC in
HMGB1 secretion. Thus, we propose that cPKC is an effector kinase of HMGB1 phosphorylation in LPS-stimulated monocytes
and PI3K-phosphoinositide-dependent kinase 1 may act in concert to control HMGB1 secretion independent of the NF-B, p38,
and ERK pathways. The Journal of Immunology, 2009, 182: 5800–5809.
H igh-mobility group box 1 (HMGB1)4 protein is a nuclearprotein that was recently found to trigger inflammation,including sepsis (1, 2). Furthermore, HMGB1 can bind
to LPS (3) and IL-1 (4) and synergize the inflammatory response.
HMGB1 is passively released by necrotic cells, but not by apopto-
tic cells, and is actively released from activated monocytes and mac-
rophages (2, 5) after proinflammatory stimuli, such as LPS, TNF-,
IL-1, IL-6, and IL-8 (6), and the modification of HMGB1 by phos-
phorylation (7) and acetylation (5). Thus, the regulation of secretion is
important in the control of HMGB1-mediated inflammation, but the
secretion mechanism is poorly understood.
It was previously shown that the shuttling of HMGB1 be-
tween the nucleus and the cytoplasm is tightly controlled by the
phosphorylation of the two nuclear localization signals
(NLS) of HMGB1 (7). When HMGB1 is phosphorylated, nu-
clear HMGB1 is translocated to the cytoplasm and cytoplasmic
HMGB1 reduces its binding to the nuclear cargo carrier protein
of karyopherin-1 (7), resulting in the eventual secretion
of HMGB1 into the extracellular space. However, the
kinase enzyme for HMGB1 phosphorylation has not been
identified.
When LPS is introduced into the circulation, it binds to LPS-
binding molecules such as LPS-binding protein (8) or HMGB1 (3)
and is transferred to CD14 and then the TLR4-MD2 receptor to
initiate LPS-mediated signaling (9). LPS signaling in human
monocytes involves the IB kinase-NF-B pathway and activates
numerous protein kinases, including MAPKs (p38, ERK, and
JNK) and PI3K (for review, See Refs. 10 and 11). However, it is
controversial whether the effect of the PI3K-Akt pathway in LPS
signaling positively or negatively affects the inflammatory re-
sponse (12–14). The prominent target of PI3K is phosphoinositide-
dependent kinase 1 (PDK1), which regulates protein kinase B
(Akt) (15, 16), p70s6k (17), and protein kinase C (PKC) (18, 19).
PKC is a family of serine/threonine enzymes and plays an impor-
tant role in many signal pathways, including those involved in
inflammation (for review, see Refs. 20 and 21). PKC has many
isoenzymes classified into three subgroups: calcium- and diacyl-
glycerol (DAG)-dependent classical PKC (cPKC; , I, II, and
), calcium-independent and DAG-dependent novel PKC (nPKC;
, , , and ), and calcium- and DAG-independent atypical PKC
(	 and 
).
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In the present report, we sought to determine which effector kinase
is involved in HMGB1 phosphorylation associated with secretion. We
tested various inhibitors of LPS-stimulated signal pathways to identify
the pathway regulating HMGB1 secretion. We show that the inhibi-
tions of cPKC and the upstream kinases PDK1 and PI3K reduced
LPS-stimulated HMGB1 secretion in RAW264.7 cells and human
peripheral blood monocytes (PBMo). We also determined that cal-
cium is important for the secretion of HMGB1. Our in vitro kinase
assay revealed that cPKC is the effector kinase of HMGB1 phosphor-
ylation that is necessary for secretion.
Materials and Methods
Cell culture and recombinant HMGB1 proteins
Murine macrophage RAW264.7 cells (American Type Culture Collection)
and human peripheral blood monocytes (PBMo) were cultured at 37°C
under 5% CO2 in DMEM supplemented with 10% FBS (Life Technolo-
gies), 100 U/ml penicillin, 100 g/ml streptomycin, and 2 mM L-glu-
tamine. Human PBMo cells were harvested from the adhesive cells on the
culture flask as previously described after obtaining the permission of the
institutional review board.
Six His-tagged wild-type (WT) HMGB1 and HMGB1 NLS1/2A pro-
teins were purified from Escherichia coli BL21 (DE3) pLysE using Ni2-
NTA, Sephadex G75, and ion-exchange columns (7). HMGB1 NLS1/2A is
a mutant protein in which the phosphorylation candidate sites at serines 35,
39, 42, 46, and 53 within or close to NLS1 and serine 181 within NLS2 are
mutated into alanine (7).
Western blot analysis
To analyze the amount of HMGB1 secretion in the supernatant, we performed
a Western blot analysis as previously described (7). Briefly, RAW264.7 and
human PBMo cells were replaced with serum-free OPTI-MEM medium (In-
vitrogen) and pretreated with each signal pathway inhibitor (see below) for 1 h
before LPS treatment and incubated for another 20 h in the presence of 1
g/ml LPS (E. coli 0111:B4; Sigma-Aldrich). The culture supernatants were
concentrated with Amicon Centricon filtration (Millipore) after removing cell
debris. The protein samples were analyzed on 12% SDS-PAGE. Rabbit anti-
HMGB1 (Abcam) and HRP-labeled goat anti-rabbit Ig (Sigma-Aldrich) were
used as primary and secondary Abs, respectively, for Western blotting. The
signals were revealed with ECL (Labfrontier).
To observe which signaling pathway is involved in HMGB1 secretion,
we used inhibitors of NF-B, MAPKs, PI3K, and downstream pathways.
The NF-B inhibitors SN50 and BAY 11-7082 (BAY-11) and the MAPK
inhibitors SB203580 (p38 inhibitor), PD098059 (ERK1/2 inhibitor), and
SP600125 (JNK inhibitor) were purchased from Calbiochem. We used
wortmannin (Calbiochem), LY294002 (A.G. Scientific), and ZSTK474
(Alexis) for PI3K inhibition, Akt inhibitor IV (Merck) for Akt inhibition,
rapamycin (Cell Signaling) for mammalian target of rapamycin (mTOR),
OSU03012 for PDK1, Go¨6983 for broad-spectrum PKC (22), Go¨6976 for
PKC and I (23) and Ro-31-7549 for PKC, I, II, , and  (24) (all
from Calbiochem). ZSTK474 is a highly specific PI3K inhibitor with 20-
fold greater activity than LY294002 (25). RAW264.7 cells were treated
with PMA (Sigma-Aldrich) for 18 h and bryostatin-1 (Calbiochem) for
20 h to activate cPKC and nPKC (26, 27). To observe the effect of intra-
cellular calcium on HMGB1 secretion, the cells were treated with the cal-
cium ionophore A23187 (Sigma-Aldrich) for 30 min to increase the cal-
cium level in tyroid buffer (137 mM NaCl, 2.7 mM KCl, 1.8 mM CaCl2,
1.1 mM MgCl2, 11.9 mM NaHCO3, 0.4 mM NaH2PO4, and 5.6 mM glu-
cose, pH 7.2) and then incubated with fresh culture medium in the absence
of A23187 for the indicated times. To block intracellular calcium signaling,
the cells were pretreated with a mixture of BAPTA-AM (Calbiochem) and
EGTA 1 h before LPS treatment and then further incubated for 18 h in the
presence of LPS.
MTT cytotoxicity assay
A MTT (Sigma-Aldrich) cytotoxicity assay was performed for each inhibitor
before treatment to exclude the possibility of HMGB1 release by cell necrosis.
For this, 2 104 cells/well of RAW264.7 were cultured in 96-well plates and
treated with each inhibitor for 20 h. MTT (Sigma-Aldrich) was treated for an
additional 4 h at 1 mg/ml. The precipitate was solubilized with DMSO after
discarding the supernatant. OD was measured at 570 nm.
In vitro kinase assay of HMGB1
To investigate the effector kinase that is involved in HMGB1 phosphory-
lation, we performed an in vitro protein kinase assay. For the assay, we
incubated 2 g of WT HMGB1 and HMGB1 NLS1/2A proteins with 20 ng
of recombinant cPKC mixture (isoenzymes , , and ; Upstate Biotech-
nology) and 5 Ci [-32P]ATP (Amersham Pharmacia Biotech) in a total
volume of 30 l of buffer, which was composed of assay dilution buffer II
(20 mM MOPS (pH 7.2), 25 mM -glycerophosphate, 1 mM sodium or-
thovanadate, 1 mM DTT, and 1 mM CaCl2), lipid activator (10 M PMA
and 0.28 mg/ml phosphatidylserine in a 0.3% Triton X-100 mixed micelle
suspension), PKA/CAMK inhibitor mixture (Upstate Biotechnology), 75
M ATP, and 10 mM MgCl2 for PKC reaction. For the casein kinase II
(CK II) reaction, 500 U of CK II (NEB) was used in the buffer, which was
composed of 20 mM Tris-HCl (pH 7.5), 50 mM KCl, 10 mM MgCl2, and
50 M ATP. For the cdc2 reaction, 20 U of cdc2 (NEB) was used in the
buffer, which was composed of 20 mM Tris-HCl (pH 7.5), 10 mM MgCl2,
1 mM EGTA, 2 mM DTT, and 50 M ATP. All of the reactions were
performed at 30°C for 30 min and terminated by adding 5 sample buffer.
The samples were separated with 12% SDS-PAGE and autoradiography
was performed after drying.
To observe the dose-dependent change in HMGB1 phosphorylation, we
incubated various amounts of HMGB1 protein with a constant amount of
cPKC in the presence of [-32P]ATP. The mixtures were transferred to p81
phosphocellulose squares (Upstate Biotechnology) followed by washing
twice with 0.75% phosphoric acid and once with acetone. Then, we de-
termined the cpm with a beta scintillation counter (Beckman Coulter).
Next, to investigate whether HMGB1 phosphorylation is specific to cPKC,
we performed an in vitro kinase assay with HMGB1 and cPKC in the
presence of various amounts of Go¨6983 and then we measured the cpm.
The in vitro kinase assay was also performed using cPKC purified from
the nuclear extracts of RAW264.7 cells. To prepare nuclear cPKC from
RAW264.7 cells, the nuclear fraction was collected using a nuclear extract
kit (Active Motif). The nuclear pellet was lysed in lysis buffer (20 mM
HEPES, 25% glycerol, 5 mM MgCl2, 1 mM CaCl2, 2 mM DTT, and 100
mM NaCl) and then resuspended by at least 30 strokes with a Dounce
homogenizer. The purity of the nuclear protein was tested by probing a
Western blot for -tubulin. The extract was centrifuged at 13,000 rpm for
30 min at 4°C and precleared by incubation with 20 l of protein G-
Sepharose (Amersham Biosciences) for 1 h at 4°C on a rocker. We incu-
bated 1 mg of the nuclear lysate protein with 5 g of anti-cPKC Ab for 2 h
at 4°C and then added protein G-Sepharose and incubated the mixture
overnight at 4°C. The immune complexes were washed with MOPS buffer
(20 mM MOPS (pH 7.2), 1 mM Na3VO4, 0.5 mM DTT, 10 mM MgCl2, 1
mM CaCl2, 10 mM NaF, 1 g/ml aprotinin, 1 g/ml leupeptin, and 1
g/ml pepstatin A) and an in vitro kinase assay was performed as described
above.
Each PKC, , and  isoenzyme was purified from the whole cell ly-
sates of RAW264.7 for the in vitro kinase assay. RAW264.7 cells were
treated with Nonidet P-40 lysis buffer (20 mM Tris-HCl (pH 7.6), 2 mM
EDTA, 1 mM PMSF, 0.5 mM DTT, 1 mM Na3VO4, 10 mM NaF, 150 mM
NaCl, 1% Nonidet P-40, 1 g/ml aprotinin, 1 g/ml leupeptin, and 1 g/ml
pepstatin A) for 30 min at 4°C. The lysates were precleared by incubation
with protein G-Sepharose. Three milligrams of whole cell lysate protein
was incubated with 1 g of each mAb to PKC, PKC, and PKC (BD
Biosciences) for 2 h at 4°C and then immunoprecipitated with protein
G-Sepharose for 1.5 h at 4°C for an in vitro kinase assay.
Knockdown of PDK1 expression with short hairpin RNA
(shRNA)
To investigate the effect of PDK1 on the secretion of HMGB1, a PDK1-
specific shRNA construct was used to knockdown PDK1 expression.
RAW264.7 cells in 24-well culture plates were transfected with 1–5 g of
HuSH 29-mer PDK1 shRNA plasmid (OriGene Technologies; CTGCG
GCAAGAGTTGCCTGTCAGACTGGC) containing puromycin selection
marker using FuGENE 6 (28). The transfected cells were selected for 24 h
by addition of 1 g/ml puromycin after transfection. Mock shRNA (Ori-
Gene Technologies) was also used for the control. Puromycin-selected
RAW264.7 cells were treated with 1 g/ml LPS for the indicated time. The
culture supernatants were prepared for SDS-PAGE to observe HMGB1
secretion, and whole cell lysates (10 g) were resolved to observe the
knockdown of PDK1 protein. PDK1 expression ranging from 58 to 68 kDa
was tested using anti-PDK1 Ab (Upstate Biotechnology). Anti-GAPDH Ab
(Lab Frontier) was used for the loading control.
To observe the interaction between PDK1 and PKC, RAW264.7 cells
were transfected with PDK1 shRNA and selected with puromycin for 24 h.
Puromycin-selected cells were treated with 1 g/ml LPS for 16 h and
whole cell lysates were analyzed to observe the phosphorylation of PKC.
Anti-phospho-panPKC Ab (Cell Signaling), which detects endogenous
phosphorylation of PKC, I, II, , , , and  isoforms at a carboxyl-
terminal residue, was used to detect PKC activation.
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Confocal imaging
To observe the translocation of cPKC and HMGB1 proteins in the
RAW264.7 cells after LPS treatment, we used immunofluorescence stain-
ing. The RAW264.7 cells were cultured in LabTek II chambers (Nalgene)
and treated with 1 g/ml LPS for the indicated times. The cells were fixed
in 3.7% paraformaldehyde-PHEM buffer (60 mM PIPES, 25 mM HEPES,
10 mM EGTA, and 4 mM MgSO4, pH 7.0) for 20 min at room temperature
(RT). After fixation, the cells were washed with cold PBS and incubated
for 5 min at 4°C with HEPES-based permeabilization buffer containing 10
mM PIPES, 0.5% Triton X-100, 300 mM sucrose, 100 mM NaCl, 3 mM
MgCl2, 1 mM EGTA, and 1 mM PMSF. The cells were blocked with 1%
BSA in PBS for 20 min after washing and were incubated with rabbit
anti-HMGB1 and mouse monoclonal anti-cPKC Abs for 2 h at RT. After
three washes, Alexa Fluor 488-conjugated goat anti-rabbit Ig (Invitrogen)
and Alexa Fluor 594-conjugated donkey anti-mouse IgG (Invitrogen) were
added and incubated for 1 h at RT. All staining was performed at the same
time. After mounting with 4,6-diamidino-2-phenylindole, the cells were
observed with a confocal LSM 510 microscope (Zeiss) and the mean flu-
orescence intensity of 10 nuclei was measured.
Coimmunoprecipitation of HMGB1 and PKC
RAW264.7 cells were treated with 1 g/ml LPS for the indicated time and
the nuclear extracts were harvested as described above. The nuclear extract
(500 g) was incubated overnight with 2 g of anti-HMGB1 in the pres-
ence of 20 l of 50% (v/v) protein G-Sepharose at 4°C. After three washes
with PBS, the precipitated complexes were solubilized by boiling in SDS
buffer. Western blotting was performed using anti-PKC and anti-PKC.
The membrane was reblotted with anti-HMGB1.
Inhibition of HMGB1 phosphorylation in RAW264.7 cells
To investigate whether LPS-stimulated phosphorylation of HMGB1 is in-
hibited by PKC inhibitor or calcium chelators, RAW264.7 cells were pre-
treated with 5 M Go¨6983 or 5 M BAPTA-AM plus 1 mM EGTA and
then treated with 1 g/ml LPS for 16 h. Whole cell lysates were prepared
and immunoprecipitated with anti-HMGB1 Ab and reblotted with anti-
phospho-Ser (pSer) PKC substrate Ab (Cell Signaling).
To observe whether LPS-stimulated migration of nuclear HMGB1 into
the cytoplasm is impaired by the above treatments, nuclear and cytoplasmic
subcellular fractions were prepared using a Qproteome Cell Compartment
kit (Qiagen) and HMGB1 was detected by Western blotting using
anti-HMGB1 Ab.
Results
LPS-stimulated HMGB1 secretion is mediated by PI3K, not by
NF-B or MAPKs pathways
In this study, we observed HMGB1 secretion in RAW264.7 and
human PBMo cells using various inhibitors of the LPS-stimulated
signal pathway to understand the relationship between phosphor-
ylation and secretion of HMGB1 (7). First, we looked at the effect
of the NF-B inhibitors SN50 and BAY-11 on HMGB1 secretion.
Both inhibitors affect different processes; SN50 inhibits the trans-
location of NF-B into the nucleus and BAY-11 inhibits IB phos-
phorylation, resulting in decreased expression of free NF-B.
RAW264.7 cells were pretreated with each inhibitor for 1 h and
further incubated for 20 h in the presence of 1 g/ml LPS.
HMGB1 secretion in the culture supernatants was not decreased by
either of the NF-B inhibitors (Fig. 1A).
We next tested the involvement of three MAPK pathways using
SB203580 (p38 inhibitor), PD098059 (ERK1/2 inhibitor), and
SP600125 (JNK inhibitor). SB203580 and PD098059 showed no
FIGURE 1. Secretion of HMGB1
is reduced by inhibitors of PI3K, but
not of NF-B and the MAPKs p38,
ERK, and JNK. RAW264.7 and hu-
man PBMo cells were pretreated for
60 min with various amounts of the
inhibitors SN50 and BAY-11 for
NF-B (A), SB203580 for p38,
PD098059 for ERK1/2, and
SP600125 for JNK (B) and wortman-
nin, LY294002, and ZSTK474 for
PI3K (C-1 and C-2), and then treated
with 1 g/ml LPS for 20 h. The cul-
ture supernatants were harvested and
Western blot analyses were per-
formed to measure HMGB1 secre-
tion. All of the tests were repeated at
least two or three times depending on
the experiment. The dot line indicates
the cut line of the same blot mem-
brane. D, MTT assay data are shown
at the maximum treatment concen-
tration of each inhibitor using
RAW264.7 cells. M, Medium;
SB20, SB203580; PD98, PD98059;
SP60, SP600125; Wort, wortman-
nin; LY29, LY294002.
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effect on HMGB1 secretion, but SP600125 inhibited LPS-stimu-
lated HMGB1 secretion in RAW264.7 cells (Fig. 1B), confirming
the previous results (29, 30).
We also tested the involvement of PI3K and its related pathways
in HMGB1 secretion, since LPS treatment rapidly influences PI3K
in both RAW264.7 and human PBMo cells (31, 32). When
RAW264.7 cells were treated with wortmannin, LY294002, and
ZSTK474, a highly specific PI3K class IA and IB inhibitor (25),
LPS-stimulated HMGB1 secretion was decreased in a dose-depen-
dent manner by these inhibitors (Fig. 1C-1). This inhibition was
also observed in human PBMo cells (Fig. 1C-2), suggesting that
PI3K is involved in LPS-stimulated HMGB1 secretion. The MTT
assay data of each inhibitor (Fig. 1D) and the background level of
HMGB1 secretion by treatment of the inhibitor alone showed that
these results were not due to necrotic RAW264.7 cells by the
inhibitors.
PKC is involved in LPS-stimulated HMGB1 secretion
Next, we treated RAW264.7 cells with Akt inhibitor IV to further
investigate the involvement of Akt, the downstream molecule of
PI3K, since Akt functions in concert with PI3K to block LPS-
stimulated NO production (32). HMGB1 secretion, however, was
not reduced by Akt inhibition (Fig. 2A). When rapamycin was used
to inhibit mTOR, the downstream target of Akt that has been
shown to have in vivo protein kinase activity (33, 34), HMGB1
secretion was not reduced in the RAW264.7 cells (Fig. 2A). This
finding suggests that LPS-stimulated secretion of HMGB1 is re-
lated to PI3K, but not to Akt-dependent pathways.
We treated RAW264.7 cells with a broad-spectrum PKC inhib-
itor, Go¨6983, to investigate the involvement of PKC (22). Go¨6983
inhibited LPS-stimulated HMGB1 secretion in a dose-dependent
manner (Fig. 2B-1). When RAW264.7 cells were treated with
Go¨6976, a selective inhibitor of PKC, I (23), HMGB1 secretion
was inhibited. Ro-31-7549, another selective cPKC, I, II, ,
and  inhibitor (24), also inhibited HMGB1 secretion in
RAW264.7 cells (Fig. 2B-1). When human PBMo cells were
treated with Go¨6983, Go¨6976, and Ro-31-7549, HMGB1 secre-
tions were similarly reduced by each of these inhibitors in a dose-
dependent manner (Fig. 2B-2). The MTT cytotoxicity assay data of
inhibitors are shown in Fig. 2D.
To further investigate the involvement of PKC, we activated
PKC and measured the HMGB1 secretion in RAW264.7 cells. For
this experiment, RAW264.7 cells were treated with PMA, a tumor-
promoting phorbol ester, in the absence of LPS. PMA (also called
12-O-tetradecanoylphorbol-13-acetate) (35) is a surrogate of DAG
and activates the cPKC and nPKC isoenzymes. HMGB1 secretion
was increased in a dose-dependent manner with PMA treatment
(Fig. 2C). When RAW264.7 cells were treated with another PKC
activator, bryostatin-1, which is a macrocyclic lactone that acti-
vates cPKC and nPKC activity (36–38), HMGB1 secretion was
slightly increased in a dose-dependent manner (Fig. 2C). Because
the up-regulated PKC activity by bryostatin-1 is rapidly down-
regulated (36–38), the increment of HMGB1 secretion seemed to
be slight. These results suggest that PKC, specifically cPKC, is
important in LPS-stimulated HMGB1 secretion.
PDK1 is involved in LPS-stimulated HMGB1 secretion
PDK1 is another downstream target of PI3K that regulates many
PKC isoenzymes such as PKC, I, , , 	, and 
 (18, 19). When
RAW264.7 cells were treated with the PDK1 inhibitor OSU03012,
FIGURE 2. Secretion of HMGB1
is related to PKC. A and B,
RAW264.7 cells were pretreated with
the downstream inhibitors of PI3K:
Akt inhibitor IV and rapamycin for
Akt and mTOR inhibition, respec-
tively. The secreted HMGB1 in the
culture supernatants was measured.
B-1 and B-2, RAW264.7 and human
PBMo cells were pretreated with
Go¨6983, Go¨6976, and Ro-31-7549,
and LPS-stimulated HMGB1 secre-
tion was measured. The dot line indi-
cates the cut line of the same blot
membrane. C, RAW264.7 cells were
treated with PMA and bryostatin-1 in
the absence of LPS for 18–20 h and
HMGB1 in the culture supernatant
was measured. All of the tests were
repeated at least two or three times
depending on the experiment. D,
MTT assay data are shown at the
maximum treatment concentration of
each inhibitor. Akt IV, Akt inhibitor
IV; Rapa, rapamycin; Ro-31,
Ro-31-7549.
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the secretion of HMGB1 was reduced in a dose-dependent manner
(Fig. 3A). Next, we used a PDK1-specific shRNA construct to
knockdown PDK1 expression. PDK1 expression was suppressed
efficiently by the PDK1 shRNA2 construct (Fig. 3B). HMGB1
secretion was not induced by LPS treatment in PDK1 shRNA-
transfected RAW264.7 cells, while HMGB1 secretion was induced
16 h after LPS treatment in mock shRNA-transfected RAW264.7
cells (Fig. 3, C-1 and C-2), confirming the involvement of PDK1
on HMGB1 secretion. To investigate whether the influence of
PDK1 on HMGB1 secretion is mediated by PKC expression, PKC
expression was measured in PDK1 shRNA-transfected RAW264.7
cells. When RAW264.7 cells were treated with LPS, endogenous
phosphorylation of PKC isoforms, 80 kDa (39), could be ob-
served (Fig. 3D, upper). LPS-stimulated PKC phosphorylation,
however, was inhibited when PDK1 expression was knocked down
by shRNA transfection (Fig. 3D, lower). These results suggest that
PDK1 knockdown by shRNA efficiently suppressed LPS-stimu-
lated PKC expression.
In vitro phosphorylation of HMGB1 by cPKC
To further examine whether cPKC is directly involved in HMGB1
phosphorylation, we performed an in vitro kinase assay. For this
assay, we tested a mixture of cPKC isoenzymes (, , and ) and
two other serine/threonine-specific protein kinases, CK II and
cdc2. CK II and cdc2 enzymes were included because they have
been reported to phosphorylate HMG-I, a HMG family protein
(40–43). We used the same amounts of WT HMGB1 and mutant
HMGB1 NLS1/2A proteins as the substrate proteins (Fig. 4A). As
shown in Fig. 4B, HMGB1 WT was heavily phosphorylated by
cPKC and detected as a band at the correct molecular weight for
HMGB1. HMGB1 NLS1/2A protein, however, was present in se-
verely diminished or only traceable levels. CK II and cdc2, how-
ever, did not show phosphorylation of either WT or mutant
HMGB1 proteins, although the phosphorylation of different mo-
lecular mass proteins that may have originated from E. coli were
present.
Next, an in vitro kinase assay using cPKC was performed with
various amounts of WT HMGB1 protein. HMGB1 phosphoryla-
tion could be observed in a dose-dependent manner by autoradiog-
raphy (Fig. 4C, upper). And the radioactivities of the phosphory-
lated HMGB1 were also increased with increasing amounts of
HMGB1 by a beta scintillation counting assay (Fig. 4C, lower).
Furthermore, the phosphorylation of HMGB1 was decreased by
the addition of Go¨6983 (Fig. 4D, upper and lower), demonstrating
that cPKC is directly involved in HMGB1 phosphorylation.
cPKC is translocated to the nucleus after LPS stimulation and
phosphorylates HMGB1
HMGB1 is a nuclear protein that must be phosphorylated in the
nucleus to translocate to the cytoplasm for eventual secretion into
the extracellular space after LPS stimulation. To investigate
whether HMGB1 is phosphorylated in the nucleus, RAW264.7
cells were treated with LPS for various times and the nuclear trans-
location of cPKC isoenzymes from the cytoplasm was observed
using a confocal microscope. In the medium-alone treatment,
cPKC was observed in the cytoplasm and HMGB1 was located in
FIGURE 3. PDK1 is involved in HMGB1 secretion. A, RAW264.7 cells were pretreated with OSU03012 and the secretion of HMGB1 in response to
LPS was measured in the culture supernatants. B, RAW264.7 cells were transfected with PDK1 shRNA constructs and selected with 1 g/ml puromycin
for 24 h. PDK1 protein expression was measured by Western blotting. GAPDH was for loading control. C-1 and C-2, RAW264.7 cells were transfected
with PDK1 shRNA2 or mock construct; LPS (1 g/ml) was treated for the indicated time after puromycin selection. The culture supernatants were resolved
by SDS-PAGE to observe HMGB1 secretion and whole cell lysates were resolved to observe the knockdown of PDK1 protein. The dotted line indicates
the cut line of the same blot membrane. D, RAW264.7 cells were treated with LPS for the indicated time, and PKC phosphorylation was measured in whole
cell lysates by Western blot analysis using anti-phospho-panPKC Ab. To observe the effect of PDK1 on PKC activation, RAW264.7 cells were transfected
with PDK1 shRNAs or mock shRNA and selected with puromycin for 24 h. Puromycin-selected cells were treated with 1 g/ml LPS and whole cell lysates
were resolved for phospho-PKC. The membrane was reblotted with PDK1 and GAPDH.
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the nucleus. cPKC began to be observed in the nuclei from 5 min
after LPS treatment and the nuclear cPKC level peaked at 20 min.
Then, the nuclear cPKC level decreased and eventually reached the
baseline or lower at 2 h after LPS treatment. At 18 h, cPKC could
not be nearly observed in the nucleus and was also reduced in the
cytoplasm, confirming the previous report of down-regulation of
activated PKC after stimulation (37). At 18 h, typical secretory
HMGB1 granules were clearly observed in the cytoplasm after
translocation (Fig. 5A). The mean fluorescence intensity of nuclear
cPKC is shown in Fig. 5B.
To observe whether the translocated cPKC directly interacts with
HMGB1 protein in the nucleus upon LPS stimulation, nuclear extract
was isolated from LPS-treated RAW264.7 cells and immunoprecipi-
tated with anti-HMGB1 for immunoblotting. When the membrane
was blotted with anti-PKC and anti-PKC, each PKC isoenzyme
could be observed 20 min after LPS treatment (Fig. 5C).
We next measured the change of cPKC activity in the nucleus
before and after LPS treatment. For this, cPKC was purified by the
immunoprecipitation method from the nuclei of RAW264.7 cells
that were treated with medium or LPS for 20 min. HMGB1 phos-
phorylation by nuclear cPKC purified from LPS-treated cells was
50% higher than that of the medium-treated control. The radio-
activity was significantly reduced in the presence of Go¨6976 (Fig.
6A). We next measured whether the PKC inhibitor impairs
HMGB1 phosphorylation and HMGB1 translocation to the nu-
cleus in RAW264.7 cells. RAW264.7 cells were treated with LPS
FIGURE 4. In vitro kinase assay
of HMGB1 phosphorylation. A,
Amino acid sequence map of WT and
NLS1/2A mutant HMGB1 proteins.
B, WT and NLS1/2A mutant HMGB1
proteins were produced in E. coli and
in vitro kinase assays were performed
using cPKC, CK II, and cdc2 en-
zymes. Both proteins were analyzed
with 12% SDS-PAGE and autora-
diography was performed. C, An in
vitro kinase assay of HMGB1 using
cPKC was performed by incubating
various amounts of HMGB1 with a
constant amount of cPKC. The phos-
phorylation levels were analyzed by
autoradiography and a beta scintilla-
tion counter. D, The mixtures of
HMGB1 and cPKC were incubated
with various amounts of Go¨6983 and
the phosphorylation levels were ana-
lyzed. The data in C and D are from
separate studies.
FIGURE 5. cPKC migration into
the nucleus in RAW264.7 cells after
LPS treatment. A and B, RAW264.7
cells were treated with 1 g/ml LPS
and cultured for the indicated time.
The cells were fixed and observed by
confocal microscopy after staining
with anti-cPKC and anti-HMGB1
Abs. All immunofluorescent staining
was performed at the same time. Bar,
5 m. The mean fluorescence inten-
sity (MFI) of 10 nuclei was mea-
sured for cPKC. C, RAW264.7 cells
were treated with 1 g/ml LPS for the
indicated time. Nuclear extracts were
harvested and immunoprecipitated
with anti-HMGB1 Ab and protein G-
Sepharose for Western blot analysis.
The membrane was immunoblotted
with anti-PKC and anti-PKC Abs
and reblotted with anti-HMGB1 Ab.
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in the presence or absence of Go¨6983. LPS-stimulated HMGB1
phosphorylation was reduced by Go¨6983 in Western blot analysis
using whole cell lysates (Fig. 6B, upper). The migration of nuclear
HMGB1 to the cytoplasm was also impaired by Go¨6983 (Fig. 6B,
lower).
cPKC has three isoenzymes of ,  (I and II), and . We next
investigated each isoenzyme activity of cPKC for HMGB1 phos-
phorylation. An in vitro kinase assay of HMGB1 was performed
using a same amount of recombinant PKC, , and . PKC was
the main kinase of HMGB1 and the activities of PKC and PKC
for HMGB1 phosphorylation were 13 and 70% of PKC, re-
spectively (Fig. 7A). Then, each PKC, , and  was purified from
the same amount of whole cell lysate of RAW264.7 cells by im-
munoprecipitation to investigate which isoenzyme is involved in
HMGB1 phosphorylation in RAW264.7 cells. As shown in Fig.
7B, PKC was the main kinase of HMGB1 in RAW264.7 cells and
both PKC and PKC, which were similarly 58% of PKC
activity, were also involved. PKC, , and  isoenzymes could be
detected in RAW264.7 cells by Western blot analysis after immu-
noprecipitation (Fig. 7C). These results show that HMGB1 is
phosphorylated by cPKC in the nucleus after LPS treatment and
translocated to the cytoplasm.
HMGB1 secretion is Ca2 dependent
We examined the involvement of calcium signaling in HMGB1
secretion because cPKC activity is Ca2 dependent. To observe
whether Ca2 is involved in HMGB1 secretion, RAW264.7 cells
were treated with the Ca2 ionophore A23187 for 30 min without
LPS treatment and then the A23187 was removed by washing and
the cells were maintained for subsequent measurements. We found
that the HMGB1 secretion was highly increased (Fig. 8A). When
human PBMo cells were treated with A23187, the secretion of
HMGB1 almost reached its peak level at just 6 h after treatment
(Fig. 8A), not necrotic cells (Fig. 8D). Next, we pretreated
RAW264.7 with BAPTA-AM and EGTA and then cultured the
cells in the presence of LPS for another 20 h. BAPTA-AM is
known to trap intracellular Ca2 and inactivate cPKC (44, 45).
Secretion of HMGB1 in RAW264.7 cells was inhibited by
BAPTA-AM in a dose-dependent manner and similar results were
FIGURE 6. PKC inhibition reduces LPS-induced HMGB1 phosphory-
lation and its migration to the cytoplasm in RAW264.7 cells. A, RAW264.7
cells were treated with medium or LPS for 20 min and cPKC from the
nuclear fraction was purified with an immunoprecipitation method using
anti-cPKC mAb for the in vitro kinase assay of HMGB1. Levels of
HMGB1 phosphorylation were measured with a beta scintillation counter.
Go¨6976 was added at a concentration of 10 M to inhibit cPKC activity.
Western blot analysis for the purity of the nuclear fraction was performed
using anti--tubulin Ab. B, RAW264.7 cells were treated with LPS in the
presence or absence of 5 M Go¨6983 for 16 h in duplicate and whole cell
lysates were immunoprecipitated with anti-HMGB1 Ab. The membrane
was immunoblotted with anti-pSer Ab and reblotted with anti-HMGB1 Ab.
To observe the impairment of HMGB1 translocation, RAW264.7 cells
were pretreated with 5 M Go¨6983 for 1 h and then treated with LPS for
16 h. Nuclear and cytoplasmic fractions were prepared and HMGB1 was
detected by Western blot analysis using anti-HMGB1 Ab.
FIGURE 7. Involvement of PKC, , and  isoenzymes in HMGB1
phosphorylation. A, An in vitro kinase assay was performed using 2 g of
HMGB1 and 60 ng of each PKC isoenzyme as described in Materials and
Methods. Levels of HMGB1 phosphorylation were measured with a beta
scintillation counter. B, One microgram of each mAb to PKC, PKC, and
PKC was incubated with 3 mg of whole cell lysate protein of RAW264.7
cells for 2 h at 4°C and then immunoprecipitated with protein G-Sepharose
for an in vitro kinase assay. Two micrograms of HMGB1 protein was
added to each reaction and the phosphorylation level was measured. C,
Equal amounts of whole cell lysates of RAW264.7 cells were immunopre-
cipitated with anti-PKC, anti-PKC, and anti-PKC Abs, and Western
blot analysis was performed.
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observed in human PBMo cells (Fig. 8B). Next, RAW264.7 cells
were pretreated with BAPTA-AM and EGTA for 30 min and then
with LPS for 16 h to observe whether BAPTA-AM and EGTA
impair HMGB1 phosphorylation and HMGB1 translocation to the
nucleus in RAW264.7 cells. LPS-stimulated HMGB1 phosphory-
lation was reduced by BAPTA-AM and EGTA (Fig. 8C, upper)
and the translocation of nuclear HMGB1 to the cytoplasm was also
impaired (Fig. 8C, lower).
Discussion
HMGB1 phosphorylation is an important mechanism that redirects
HMGB1 for secretion (7); however, the effector kinase has not
been previously identified. In this study, we have made the novel
finding that PKC, and not CK II or cdc2, is the effector kinase for
HMGB1 phosphorylation. A well-known HMG family protein,
HMG-I(Y), can be phosphorylated by CK II (43, 46), cdc2 (41,
42), and PKC (40). It appears that the kinases that phosphorylate
proteins in the HMG family are protein specific. PKC is not a
single entity, but is a family of isoenzymes composed of three
groups: cPKC, nPKC, and atypical PKC. In a secretion inhibition
assay, cPKC inhibitors Go¨6976 and Ro-31-7549 reduce LPS-stim-
ulated HMGB1 secretion and the activators of cPKC and nPKC,
PMA and bryostatin-1, increase HMGB1 secretion. In addition,
cPKC directly phosphorylates HMGB1 in an in vitro kinase assay.
These data strongly suggest that cPKC is an effector kinase for
HMGB1 phosphorylation. Since cPKC does not have a nuclear
localization signal sequence (20, 21), it was unclear how it phos-
phorylates HMGB1 in the nucleus. A confocal microscopy study
of cPKC in the nucleus after LPS stimuli and an in vitro kinase
assay and immunoprecipitation analysis using purified nuclear
cPKC from LPS-treated RAW264.7 cells showed that cPKC can
migrate into the nucleus and bind to HMGB1 after LPS stimuli to
phosphorylate HMGB1 protein with an unknown mechanism.
PKC isoenzymes are located in the cytoplasm as an inactive state
in resting cells and are redistributed after stimuli (20, 21), and the
redistribution of PKC and PKC to the nucleus after PMA stim-
uli or hypoxic stress had been suggested in previous reports
(47, 48).
PDK1 is the downstream target of PI3K (18) and in turn regu-
lates Akt and PKC, , , , and 	 (18, 19). In our study, PKC
phosphorylation in response to LPS stimulation was inhibited by
PDK1 knockdown as shown in previous reports (18, 39). Also,
LPS-stimulated HMGB1 secretion decreased after treatment with
PDK1 inhibition, but not after treatment with the inhibitors of Akt
and mTOR, suggesting that the PI3K-PDK1-PKC signal pathway
is important for HMGB1 secretion. Of the major signaling path-
ways of NF-B and MAPKs p38, ERK, and JNK in LPS-stimu-
lated inflammation, only JNK inhibition by SP600125 reduced
HMGB1 secretion, whereas we found that the other pathways had
no effect on LPS-mediated HMGB1 secretion. This finding con-
firms previous results (29, 30), but the effect of NF-B on HMGB1
secretion is still controversial (29, 49). Although JNK inhibition
reduced LPS-stimulated HMGB1 secretion in our study and in
another group study (30), it is questionable whether the reduction
of HMGB1 secretion is the direct effect of JNK inhibition or the
indirect effect of high concentrations of the JNK inhibitor
SP600125 on cPKC activity (50). SP600125 could inhibit JNK
activity at a low concentration (IC50, 0.04 M) with a greater
selectivity against MAPKs p38 and ERK. At the higher concen-
tration, however, SP600125 could inhibit PKC (IC50, 1.5 M)
and a PKC mix (IC50, 10 M) (50) when used at the same
concentration generally used for a JNK inhibition study. In our
study, a low concentration of SP600125 under 1 M showed little
effect on LPS-mediated HMGB1 secretion but a high concentra-
tion of SP600125 over 1 M showed the reduction of HMGB1
secretion dose-dependently. Further study of the JNK effect on
HMGB1 phosphorylation and its secretion is necessary to reach a
clear conclusion.
cPKC levels rapidly increased in the nucleus around 20 min
after LPS stimulation and then seemed to reach normal levels after
FIGURE 8. HMGB1 secretion is calcium dependent. A, RAW264.7 and human PBMo cells were treated with the Ca2 ionophore A23187 for 30 min
and further incubated for the indicated time after washing out the ionophore. HMGB1 in the culture supernatant was measured by Western blot analysis.
B, RAW264.7 and human PBMo cells were pretreated with Ca2 chelating agents BAPTA-AM and EGTA for 30 min and then treated with 1 g/ml LPS
for another 20 h. HMGB1 in the culture supernatants was measured. All of the tests were repeated at least two or three times depending on the experiment.
C, RAW264.7 cells were pretreated with 5 M BAPTA-AM and 1 mM EGTA for 30 min and then treated with 1 g/ml LPS for another 16 h in duplicate.
Whole cell lysates were immunoprecipitated with anti-HMGB1 Ab. The membrane was immunoblotted with anti-pSer Ab and reblotted with anti-HMGB1
Ab. To observe the impairment of HMGB1 translocation, nuclear and cytoplasmic fractions were prepared and HMGB1 was detected by Western blot
analysis using the anti-HMGB1 Ab. D, MTT assay was performed at the maximum treatment concentration of each inhibitor using RAW264.7 cells.
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1–2 h. It is unknown why HMGB1 is translocated to the cytoplasm
several hours after its phosphorylation. In the study of phosphor-
ylation kinetics of plant maize and Arabidopsis HMGB1 proteins,
which are phosphorylated by CK II in vitro, the phosphorylation
of HMGB proteins are slow and the serial events and double phos-
phorylation are not yet completed after 60 min, suggesting that the
rate of the phosphorylation reaction is related to the ease of inter-
action between CK II and HMGB proteins (51). After phosphor-
ylation of HMGB1, its DNA-binding affinity is strongly decreased
(40) and then it binds to nuclear exportin, CRM1, for migration to
the cytoplasm (5). Considering that the simultaneous phosphory-
lation of HMGB1 at both NLS sites is important for its cytoplas-
mic relocation (7), the slow rate of HMGB1 phosphorylation may
be the reason for its slow relocation to the cytoplasm. Further
kinetic studies of HMGB1 phosphorylation are necessary for a
more exact explanation.
HMGB1 secretion is closely correlated with intracellular Ca2
level, and this finding is not surprising given that cPKC is a cal-
cium-dependent kinase. In a study of a liver ischemia model,
HMGB1 release was induced by TLR4-dependent reactive oxygen
species production in hepatocytes, and this hypoxia-induced
HMGB1 release was reduced by calcium chelation (52). Recently,
Zhang et al. (53) showed that inhibition of calmodulin (CaM) ki-
nase IV (CaMKIV) reduces nucleocytoplasmic shuttling of
HMGB1 and the release of HMGB1 into the culture supernatant in
response to LPS, suggesting CaMKIV-dependent serine phosphor-
ylation of HMGB1 (53). CaMKIV is a family member of CaMKs,
which are serine/threonine kinases that are activated by Ca2/cal-
modulin. In our study, however, the inhibitions of CaMKs with
KN-93 and of CaMK kinases with STO-609 showed almost no
change in LPS-stimulated HMGB1 secretion using RAW264.7
cells (data not shown), and further study is necessary for the clear
conclusion.
In our study, we primarily focused on cPKC, although PKC, ,
and 	 are activated in macrophages and monocytes stimulated with
LPS (54–56), because the cPKC inhibitors were effective in in-
hibiting LPS-stimulated HMGB1 secretion and cPKC was the ef-
fector kinase in the in vitro kinase assay. Each isoenzyme of cPKC
shows a kinase activity for HMGB1 phosphorylation and further
study about the involvement of PKC, , and 	 is necessary. In
conclusion, LPS-stimulated HMGB1 secretion in monocytes is pri-
marily mediated by cPKC in a calcium-dependent manner and the
PI3K-PDK1 signaling pathway may act in concert to control
HMGB1 secretion independent of the NF-B, p38, and ERK
pathways.
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